Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms

Pharmaceutical Development and Technology

Volumn 18, Issue 6, 2013, Pages 1265-1276

  Desai, Divyakant ^a   Wang, Jennifer ^a   Wen, Hong ^b   Li, Xuhong ^c   Timmins, Peter ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Pentian Pharmaceuticals Company   (China)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

An active coating; Bi layer tablet; FDC; Fixed dose combination; Formulations; HME

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; AMLODIPINE PLUS CANDESARTAN HEXETIL; ATROPINE PLUS DIPHENOXYLATE; BUPRENORPHINE PLUS NALOXONE; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; CLARITIN D; DICLOFENAC PLUS MISOPROSTOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUTASTERIDE PLUS TAMSULOSIN; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESOMEPRAZOLE PLUS NAPROXEN; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS SAXAGLIPTIN; NICOTINIC ACID PLUS SIMVASTATIN; PIOGLITAZONE; RILPIVIRINE; SULFONYLUREA; DRUG COMBINATION; DRUG DOSAGE FORM;

AGING; COMORBIDITY; COST CONTROL; DECISION TREE; DIABETES MELLITUS; DRUG COMBINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG GRANULATION; DRUG POTENTIATION; DRUG STABILITY; FILM COATING; FIXED DOSE COMBINATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; TABLET; TUBERCULOSIS; ANIMAL; DRUG DESIGN; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG COMBINATIONS; DRUG DESIGN; HUMANS;

EID: 84873177573     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.660699     Document Type: Review

References (67)

1. Luo Y, Zu Y, Ahmad S. Challenges of fixed dose combination product development. American Pharmaceutical Review 2007, 10(2): 120-126
2. Timmins P. (2006). Developing fixed combination drug products- Technical challenges and opportunities. In: The 10th Annual Drug Delivery Partnerships. Phoenix, AZ, USA
3. Pudipeddi M. (2010). Biopharmaceutical challenges in development of fixed-dose combinations. In: Eastern Pharmaceutical Technology Meeting. Somerset, New Jersey, USA.
4. Karali TT. Available at: (http://www.pharmacircle.com/presentations/fixed dose.pdf)
5. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-Analysis. Hypertension 2010;55:399-407
6. Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-533
7. Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Henneckens CH. Aggrenox and aspirin in patients after ischemic stroke: the Aggrenox versus aspirin therapy evaluation trial. Eur J Pharmacol 2004;3:315-324
8. Easton J, Noble S, Perry CM, Cuffini AM, Jacobs MR, Subba Rao SD, Pichichero ME, Thornberry C. Amoxicillin/clavunic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs 2003;23:311-340 (Pubitemid 36197502)
9. Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010;111:44-49
10. Coleman JJ, Schuster CR, Dupont RL. Reducing the abuse potential of controlled substances. Pharmaceut Med 2010;24:21-36
11. World Health Organization Expert Committee. (2000). The use of essential drugs including the revised model list of essential drugs. Geneva
12. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13 Suppl 1:S61-S72 (Pubitemid 29516023)
13. Dublin CH. Combination products: strategies for continuous pipeline. Drug Deliv Tech 2005;5:41-46
14. Lacy CF, Armstrong LL, Goldman MP, Lance LL. (2006). Drug Information Handbook. 14th edition ed. Hudson, Ohio, USA: Lexi- Comp Inc.
15. FDA Guidance for Industry. (2003). Estrogen/progestin drug products to treat vasomoto symptoms and vulvar vaginal atrophy symptoms recommendations for clinical evaluation. Rockville, MD, USA.
16. FDA Guidance for Industry. (2006). Fixed Dose combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of HIV. Rockville, MD, USA.
17. Guidance for Industry. (1999). Application covered by section 505b2, CDER, Editor. Rockville, MD.
18. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011;364:985-987
19. FDA Guidance for Industry. (2010). Co-development of Two or More Unmarketed Investigational Drugs for Use in Combination. Rockville, MD, USA.
20. World Health Organization Expert Committee. (2005). Fixed-dose combination medicinal products. Geneva, 94-142
21. Wechsler J. Combination products raise manufacturing challenges. Pharmaceut Tech 2005;29:32-40 (Pubitemid 40387769)
22. Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M. Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull 2008;56:1455-1458
23. Shiyani B, Gattani S, Surana S. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008;9:818-827
24. Mandal U, Pal TK. Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm 2008;34:305-313 (Pubitemid 351431201)
25. Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm 2008;348:27-34 (Pubitemid 350278551)
26. Streubel A, Siepmann J, Peppas NA, Bodmeier R. Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design. J Control Release 2000;69:455-468
27. Benkerrour L, Galley O, Quinet F, Abebe A, Timmins P. Multilayered tablet containing pravastatin and aspirin and method, 2004, US patent, US2004/0115265
28. Podczeck F. Theoretical and experimental investigations into the delamination tendencies of bilayer tablets. Int J Pharm 2011;408:102-112
29. Anuar MS, Briscoe BJ. Interfacial elastic relaxation during the ejection of bi-layered tablets. Int J Pharm 2010;387:42-47
30. Tye CK, Sun CC, Amidon GE. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J Pharm Sci 2005;94:465-472 (Pubitemid 40476512)
31. Li SP, Karth MG, Feld KM, Di Paolo LC, Pendharkar CM, Williams RO. Evaluation of bilayer tablet machines-A case study. Drug Dev Ind Pharm 1995;21:571-590
32. Wu CY, Jonathan P,Seville K. A comparative study of compaction properties of binary and bilayer tablets. Powder Tech 2009;189:285-294
33. Inman SJ, Briscoe BJ, Pitt KG, Shiu C. The non-uniformity of microcrystalline cellulose bilayer tablets. Powder Tech 2009; 188:283-294
34. Inman SL, Briscoe BJ, Pitt KG, Shiu C. Topographic characterization of cellulose bilayered tablets interfaces. Chem Eng Res Des 2007; 85:1005-1012 (Pubitemid 47241495)
35. Akseli I, Dey D, Cetinkaya C. Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech 2010;11:90-102
36. Gandhi R, Lal Kaul C, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today 1999;4:160-170 (Pubitemid 29195749)
37. Gainotti A, Bettini R, Gazzaniga A, Colombo P, Giordano F. Drug-?- cyclodextrin containing pellets prepared with a high-shear mixer. Drug Dev Ind Pharm 2004;30:1061-1068 (Pubitemid 39577998)
38. Mezreb N, Charrueau C, Boy P, Allain P, Chaumeil JC. Production of Carbopol 974P and Carbopol 971P pellets by extrusionspheronization: optimization of the processing parameters and water content. Drug Dev Ind Pharm 2004;30:481-490 (Pubitemid 38821859)
39. Poelvoorde N, Huyghebaert N, Vervaet C, Remon JP. Optimisation of an enteric coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur J Pharm Biopharm 2008;69:969-976
40. Abdul S, Chandewar AV, Jaiswal SB. A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS). J Control Release 2010;147:2-16
41. Kok PJAH, Von kP, Hoekzema MA, Kossen NWF. Development of particulate pulse-release formulation and their mathematical description. Powder Tech 2001;119:33-44 (Pubitemid 32758803)
42. Dashevsky A, Mohamad A. Development of pulsatile multiparticulate drug delivery system coated with aqueous dispersion Aquacoat ECD. Int J Pharm 2006;318:124-131 (Pubitemid 43963305)
43. Baki G, Bajdik J, Djuric D, Knop K, Kleinebudde P, Pintye-Hodi K. Role of surface free energy and spreading coefficient in the formulation of active agent-layered pellets. Eur J Pharm Biopharm 2010;74: 324-331
44. Cosijns A, Nizet D, Nikolakakis I, Vervaet C, De Beer T, Siepmann F et al. Porous pellets as drug delivery system. Drug Dev Ind Pharm 2009;35:655-662
45. Kranz H, Le Brun V, Wagner T. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug. Int J Pharm 2005;299:84-91 (Pubitemid 40962409)
46. Riis T, Bauer-Brandl A, Wagner T, Kranz H. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm 2007;65:78-84 (Pubitemid 44827687)
47. Qiu Y, Gupta P, Briskin J, Cheskin H, Semla S. Sustained-release multiparticulate formlations of Zileuton. I. In vitro and in vivo evaluation. Int J Pharm 1996;143:179-185 (Pubitemid 26425823)
48. Wesdyk R, Joshi YM,Vincentis JD,Newman AW,Jain NB. Factors affecting differences in film thickness of beads coated in fluidized bed units. Int J Pharm 1993;93:101-109 (Pubitemid 23181287)
49. McConnell EL, Macfarlane CB, Basit AW. An observational study on the influence of solvent composition on the architecture of drug-layered pellets. Int J Pharm 2009;380:67-71
50. Talukder R, Fassihi R. Gastroretentive delivery systems: hollow beads. Drug Dev Ind Pharm 2004;30:405-412 (Pubitemid 38987183)
51. Vasanthavada M, Wang Y, Haefele T, Lakshman JP, Mone M, Tong W et al. Application of melt granulation technology using twinscrew extruder in development of high-dose modified-release tablet formulation. J Pharm Sci 2011;100:1923-1934
52. Kowalski J. (2008). Novel opportunities for solid oral dosage form development using a twin screw extruder. In: American Association of Pharmaceutical Scientist Annual Meeting. Atlanta, GA, USA.
53. Kwan H, Liebowitz S. (1994). Stable extended release oral dosage composition comprising loratidine and pseudoephedrine. United States, 2009, US Patent 5314697.
54. Bova J, DunneJ. Combinations of HMG-COA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a at night, 2009, Publication No: WO/1999/006046
55. Charlton ST, Nicholson SJ. A novel immediate release active film coat formulation for use with an extended release gel matrix tablet core. J Pharm Pharmacol 2010;62:1397-1398
56. Lipper RD, Desai D,Kiang S. (2006). Case Study: Implementation of Design Space. In: Real World Applications of PAT and QbD in Drug Process Development and Approval. Arlington, Virginia, USA.
57. Desai D, Rao V, Guo H, Li D, Stein D, Hu FY et al. An active filmcoating approach to enhance chemical stability of a potent drug molecule. Pharm Dev Technol 2010;11:1-9
58. Carstensen JT, Koff A, Johnson JB, Rubin SH. Tablet-to-tablet variation of drug content of sugar-coated tablets containing drug in the sugar coat. J Pharm Sci 1970;59:553-555
59. Chen W, Chang SY, Kiang S, Marchut A, Lyngberg O, Wang J et al. Modeling of pan coating processes: prediction of tablet content uniformity and determination of critical process parameters. J Pharm Sci 2010;99:3213-3225
60. Hagrasy AE, Chang SY, Desai D, Kiang S. Application of Raman Spectroscopy for quantitative in-line monitoring of tablet coating. Am Pharmaceut Rev 2006;9:40-45
61. Hagrasy AE, Chang SY, Desai D, Kiang S. Raman Spectroscopy for the determination of coating uniformity of tablets: assessment of product quality and coating pan mixing efficiency during scale-up. J Pharmaceut Innovat 2006;1:37-42 (Pubitemid 46795704)
62. Chen W, Chang SY, Kiang S, Early W, Paruchuri S, Desai D. The measurement of spray quality for pan coating processes. J Pharmaceut Innovat 2008;3:1872-1875
63. Fichana D, Marchut AJ, Ohlsson PH, Chang SY, Lyngberg O, Dougherty J et al. Experimental and model-based approaches to studying mixing in coating pans. Pharm Dev Technol 2009; 14:173-184
64. Gohel MC, Jogani PD. A review of co-processed directly compressible excipients. J Pharm Pharm Sci 2005;8:76-93 (Pubitemid 41528873)
65. Mohammed GA, Puri V, Bansal AK. Coprocessing of nevirapine and stavudine by spray drying. Pharm Dev Technol 2008;13:299-310
66. Sadek H, Dietel GL. Film-enrobed unitary-core medicament and the like. U.S. Patent 5,146,730. Editor 1992
67. Li Y, Clarke AJ. (2009). A novel liquid dispensing technology for manufacturing low dose immediate release tablets. In: 2009 AAPS Annual meeting